Avenzo Therapeutics Advances Combination of AVZO-023 (CDK4i) with AVZO-021 (CDK2i) in Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer ...
Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("I ...
US companies have reported notable developments across defense, biotechnology, artificial intelligence, and electric vehicles. These include a $3.1M drone-detection testing chamber in New York, a ...
Press release - No. 9 / 2026 The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of ...
Earlier today, Nautilus Biotechnology released financial results for the quarter ended March 31, 2026. If you haven't received this news release or if you'd like to be added to the company's ...
A wave of landmark microbiology studies is redefining how scientists understand, manipulate, and conserve microbial life.
Company secures $5M in funding to accelerate its rapid testing platformUSP Validation achieved, reinforcing 20-hour testing methodFaster test results replace the standard 14-day USP sterility test SAN ...
PBM reform championed by Sen. Warner is a necessary step to lower health care costs for patients, VA Bio’s John Newby writes ...
Pitt Street Research and Euroz Hartleys have released research notes on Dimerix highlighting upside potential as progresses ...
Building on landmark Nature Biotechnology findings, Nutromics secures AU$3 million in a AU$11.2 million consortium to ...
Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug ...
Gubra today notes that its partner Boehringer Ingelheim plans to initiate Phase 2 clinical development in mid-2026 of BI 3034701, an investigational, potential first-in-class triple GLP-1, GIP and NPY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results